Search results
Results from the WOW.Com Content Network
The principal for obstetric management of COVID-19 include rapid detection, isolation, and testing, profound preventive measures, regular monitoring of fetus as well as of uterine contractions, peculiar case-to-case delivery planning based on severity of symptoms, and appropriate post-natal measures for preventing infection.
The Randomised Evaluation of COVID-19 Therapy (RECOVERY Trial) [1] is a large-enrollment clinical trial of possible treatments for people in the United Kingdom admitted to hospital with severe COVID-19 infection. [2] [3] [4] The trial was later expanded to Indonesia, Nepal and Vietnam. [5]
In March, the Centers for Disease Control and Prevention (CDC) updated its COVID isolation guidelines based on symptoms, not time since testing positive. The guidelines shifted in part to match ...
Failure has often been attributed to the delay in receiving treatment (greater than 72 hours post-exposure), the level of exposure, and/or the duration of treatment (lack of adherence to the 28-day regimen). In addition, since the time and level of non-occupational exposures are self-reported, there is no absolute data on the administration ...
Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic . The symptoms of COVID‑19 can vary but often include fever, [ 7 ] fatigue, cough, breathing difficulties , loss of smell , and loss of taste .
A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 , the virus that causes coronavirus disease 2019 . The COVID‑19 vaccines are widely credited for their role in reducing the spread of COVID‑19 and reducing the severity and death caused by COVID‑19.
Scanning electron micrograph of SARS virions. Severe acute respiratory syndrome (SARS) is the disease caused by SARS-CoV-1. It causes an often severe illness and is marked initially by systemic symptoms of muscle pain, headache, and fever, followed in 2–14 days by the onset of respiratory symptoms, [13] mainly cough, dyspnea, and pneumonia.
HCoV-229E is associated with a range of respiratory symptoms, ranging from the common cold to high-morbidity outcomes such as pneumonia and bronchiolitis.However, such high morbidity outcomes are almost always seen in cases with co-infection with other respiratory pathogens; there is a single published case report to date of a 229E infection that caused acute respiratory distress syndrome ...